Fierce Pharma21h
AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
조선일보1mon
Amgen and Celltrion settle patent dispute, paving way for osteoporosis biosimilars
Previously, Amgen filed patent infringement lawsuits against biosimilar companies including the Swiss Sandoz, South Korea's Celltrion, South Korea's Samsung Bioepis, and Germany's Fresenius Kabi.
The Pharma Letter13d
FDA nod for two Celltrion denosumab biosimilars
South Korea-based Celltrion today announced that the US Food and Drug Administration (FDA) has approved Stoboclo and Osenvelt ...
KED Global8d
Samsung, Celltrion lead biosimilar market in Europe, US
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz ...